Hematology-Oncology
Targeting the FGF18-FGFR3 Axis: A New Frontier in Acute Myeloid Leukemia Therapy
FGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therap
